.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Petra Zilliken

Köln

IOZK

Speaker

We, 12/06/2024
10:20 – 10:30 7 Min. 3 Min.
Abstractvortrag | Abstract talk
V230
Individualisierte multimodale Immuntherapie zusätzlich zur Standarttherapie des Glioblastomas verbessert das Überleben
Individualized multimodal immunotherapy added to standard care of glioblastoma multiforme improves the overall survival
Tumor

Further involvements

We, 12/06/2024
10:20 – 10:30 7 Min. 3 Min.
Abstractvortrag | Abstract talk
V230
Individualisierte multimodale Immuntherapie zusätzlich zur Standarttherapie des Glioblastomas verbessert das Überleben
Individualized multimodal immunotherapy added to standard care of glioblastoma multiforme improves the overall survival
Tumor